Please ensure Javascript is enabled for purposes of website accessibility

3 Top Coronavirus Stocks to Buy Right Now

By Adria Cimino - Apr 24, 2021 at 5:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Major gains may be on the horizon.

When we think of coronavirus stocks, we think of those that already have soared. But there still are stocks with promising programs -- or even commercialized products -- that haven't. In many cases, it's just a question of time. For instance, clinical-stage and early commercial-stage biotech companies have quickly climbed following positive news from their coronavirus programs. Pharmaceutical companies generally are less reactive to one piece of news. Instead, they often gain over the long term.

Here, I've chosen three stocks in the treatment and vaccine space that have plenty of potential ahead for revenue -- and stock market gains. Let's take a close look at each of these future winners.

A young woman smiles as she looks at her laptop.

Image source: Getty Images.


Regeneron Pharmaceuticals (REGN 0.20%) makes one of the two antibody treatments authorized for use today in coronavirus patients. The U.S. Food and Drug Administration granted the company Emergency Use Authorization (EUA) in November for use of its antibody cocktail in mild to moderate cases. The idea is to treat patients at risk for serious disease early so they won't need hospitalization.

The challenge so far has been the delivery method: The cocktail is given by infusion. That requires extra time and effort from healthcare facilities and potential patients. But Regeneron is tackling this issue. The company is testing the cocktail as a subcutaneous injection. And it already has positive trial data on the cocktail as a prevention method. Subcutaneous injection of the cocktail reduced risk of symptomatic infection in household contacts of coronavirus patients by 81%. Regeneron plans on requesting an EUA expansion to include this use.

The coronavirus treatment market represents significant opportunity. Morningstar last year predicted $6 billion in 2021 cocktail sales for Regeneron and European partner Roche. So far, the stock hasn't reflected this. The shares have increased about 4% year to date. And the stock is trading close to a low in relation to forward earnings estimates, so you can pick up the shares at a bargain today.

REGN PE Ratio (Forward) Chart

REGN PE Ratio (Forward) data by YCharts


Pfizer (PFE -1.28%) is the leading player in the coronavirus vaccine space. It entered the market first. And so far, it's fully vaccinated more than 43 million Americans compared with rival Moderna's 36 million. Pfizer said earlier this year that it expects to generate $15 billion in sales from its coronavirus vaccine in 2021. It shares that with partner BioNTech. But this still leaves Pfizer with a blockbuster level of revenue from the product.

Recent troubles for rivals AstraZeneca and Johnson & Johnson have offered Pfizer another boost. Europe doesn't intend on renewing coronavirus vaccine orders from the two companies, according to a report in Italian newspaper La Stampa. The European Union said it will buy 1.8 billion Pfizer vaccine doses through 2023.

Pfizer's stock price hasn't benefited from vaccine news. The stock is only up about 7% this year. That's because Pfizer has a vast array of products and investors are looking at the whole package. But good news is ahead. Pfizer recently completed the spinoff of Upjohn, a business that was holding back growth. Sales from Pfizer's blockbuster drugs like anticoagulant Eliquis and oncology drug Ibrance, as well as the coronavirus vaccine, are likely to boost earnings and the share price over time. Now is a great time to get in on this story.


Gritstone Oncology (GRTS 10.98%) doesn't yet have products on the market. But its investigational coronavirus vaccine could carve out market share if trials are successful. Here's why: The candidate includes material from the coronavirus' spike protein and other viral antigens. That means it may better handle variants than a vaccine targeting uniquely the spike. (The spike protein is used to infect.)

Gritstone late last month dosed the first participant in its phase 1 study. It expects to report initial data around midyear, so it's clear Gritstone's potential vaccine would be for use down the road. And that's OK. Experts say the coronavirus is here to stay. We'll need vaccinations and treatments well into the future.

Another interesting aspect of Gritstone's program is this: Phase 2 will study the candidate as a booster after vaccination with a currently authorized coronavirus vaccine. If all trials are successful, Gritstone could be looking at two potential audiences: those who need full vaccination and those who need booster shots only.

Gritstone shares have climbed more than 100% so far this year. But Wall Street expects them to gain 171% within the coming 12 months. If trials go well, that's very possible. But one word of caution: I recommend Gritstone for aggressive investors only. Hopes are riding on the coronavirus program right now. And that makes shares of this biotech company very vulnerable to any disappointments.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$51.64 (-1.28%) $0.67
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$596.56 (0.20%) $1.16
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.14 (-0.77%) $-1.38
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$10,800.00 (-0.07%) $-8.00
Gritstone bio, Inc. Stock Quote
Gritstone bio, Inc.
$2.73 (10.98%) $0.27
Moderna, Inc. Stock Quote
Moderna, Inc.
$155.54 (3.73%) $5.59
BioNTech SE Stock Quote
BioNTech SE
$161.03 (2.24%) $3.53
Roche Holding AG Stock Quote
Roche Holding AG
$319.00 (-1.12%) $-3.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.